Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib

Affiliations

• ¹ Imperial College, South Kensington, London, UK.
• ² Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
• ³ Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, Oxford, UK.
• ⁴ Guy's and St Thomas' NHS Foundation Trust, London, UK.
• ⁵ OHSU Knight Cancer Institute, Portland, OR, USA.
• ⁶ University of Liverpool, Liverpool, UK.
• ⁷ University of California, Los Angeles, CA, USA.
• ⁸ Blue Ridge Cancer Center, Salem, VA, USA.
• ⁹ Northwestern University, Chicago, IL, USA.
• ¹⁰ US Oncology Research, OHC, Cincinnati, OH, USA.
• ¹¹ Baylor University Medical Center, Texas Oncology, Dallas, TX, USA.
• ¹² University of Arizona Cancer Center, Tucson, AZ, USA.
• ¹³ Sarah Cannon Research Institute, London, UK.
• ¹⁴ Cancer Research UK Cambridge Centre, Cambridge, UK.
• ¹⁵ Dana-Farber Cancer Institute, Boston, MA, USA.
• ¹⁶ Carrick Therapeutics, Dublin, Ireland.
• ¹⁷ Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. matthew.krebs@manchester.ac.uk.